Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 3;9(1):1774298.
doi: 10.1080/2162402X.2020.1774298.

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Romain Daillère  1 , Lisa Derosa  2   3 , Mélodie Bonvalet  2   3 , Nicola Segata  4 , Bertrand Routy  5   6 , Manuela Gariboldi  7 , Eva Budinská  8 , I Jolanda M De Vries  9 , Alessio Gordon Naccarati  10   11 , Valérie Zitvogel  1 , Carlos Caldas  12 , Lars Engstrand  13 , Sibylle Loilbl  14 , Jacques Fieschi  15 , Lucie Heinzerling  16 , Guido Kroemer  17   18   19   20   21 , Laurence Zitvogel  2   3   20   22   23
Affiliations
Review

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Romain Daillère et al. Oncoimmunology. .

Abstract

Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. These findings have led to the design of clinical trials that evaluate the capacity of modulation of the gut microbiota to synergize with treatment and hence limit tumor progression. Along the lines of this Trial Watch, we discuss the rationale for harnessing the gut microbiome in support of cancer therapy and the progress of recent clinical trials testing this new therapeutic paradigm in cancer patients.

Keywords: Gut microbiota; anticancer therapeutics; clinical trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Therapeutic strategy involving microbial products to circumvent primary resistance to anticancer treatments.
See this image and copyright information in PMC

References

    1. Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015;42(4):523–8. doi: 10.1053/j.seminoncol.2015.05.003. - DOI - PMC - PubMed
    1. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob -J-J, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine. 2011;364(26):2517–2526. doi: 10.1056/NEJMoa1104621. - DOI - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England Journal of Medicine. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643. - DOI - PMC - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. New England Journal of Medicine. 2015;372(4):311–319. doi: 10.1056/NEJMoa1411087. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed

Publication types